Back to discover
Disease
Hereditary sensory and autonomic neuropathy type 2
Late-stage therapeutic development
Also known as HSAN2, Hereditary Sensory and Autonomic Neuropathy Type II, autosomal recessive sensory radicular neuropathy, hereditary sensory and autonomic neuropathy type II+4 more
HSAN2, Hereditary Sensory and Autonomic Neuropathy Type II, autosomal recessive sensory radicular neuropathy, hereditary sensory and autonomic neuropathy type II, neurogenic acroosteolysis, Giaccai type acroosteolysis, hereditary sensory neuropathy type 2, hereditary sensory radicular neuropathy, recessive form.
24
Clinical trials
6
Associated genes
1
Related proteins
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- Q3 2027Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)
- Q1 2028A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes Mellitus
- Q1 2028Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.
- Q2 2032Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20322026-07-10
Upcoming trial readoutHigh impact
Results expected Q1 20282026-04-30
Clinical MilestonesView all 10Hide
Results posted
Results expected
- 2026-07-10Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast CancerResults expected Q2 2032
- 2026-04-30A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-31Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.Results expected Q1 2028
- 2025-10-27Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in TreatmentResults expected Q4 2026
- 2025-09-02Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)Results expected Q3 2027
Recently completed
Other updates
- 2028-03-01A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2027-12-01Guard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2025-12-30A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainTerminated
+2 more in the activity timeline below
Activity timeline10
- 2028-03-01ClinicalA Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2027-12-01ClinicalGuard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2026-07-10ClinicalPhase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast CancerResults expected Q2 2032
- 2026-04-30ClinicalA Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-31ClinicalCapsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.Results expected Q1 2028
- 2025-12-30ClinicalA Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainTerminated
- 2025-10-27ClinicalAdhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in TreatmentResults expected Q4 2026
- 2025-10-09ClinicalAn Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral NeuropathyResults posted
- 2025-09-02ClinicalEffectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)Results expected Q3 2027
- 2025-09-01ClinicalEfficacy of Thymoquinone as an Adjuvant Treatment With Pregabalin for the Treatment of Neuropathy in Diabetic Patients: A Randomized Clinical Trial of 65 mg of Thymoquinone and 75 mg Pregabalin Daily for Two MonthsCompleted
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
HSAN2, Hereditary Sensory and Autonomic Neuropathy Type II, autosomal recessive sensory radicular neuropathy, hereditary sensory and autonomic neuropathy type II, neurogenic acroosteolysis, Giaccai type acroosteolysis, hereditary sensory neuropathy type 2, hereditary sensory radicular neuropathy, recessive form
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.